Enzyme News and Research

RSS

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Researchers from nference labs in Massachusetts have been examining the origins of a particular mutation in the Omicron variant.

5 Jan 2022

Erectile dysfunction medication found to intensify abdominal aortic aneurysms in mice

In a laboratory study in mice, sildenafil, a commonly used erectile dysfunction medication, was found to worsen abdominal aortic aneurysms, indicating additional research may be needed to determine if the medication may have the same effect on people, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

5 Jan 2022

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Results from a new study could be crucial in studying the molecular and biochemical basis of SARS-CoV-2 infection at a more granular level and help in strategizing therapeutic solutions to treat and manage COVID-19 effectively.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

4 Jan 2022

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

SARS-CoV-2 differs from other viruses in the beta coronavirus family in the activation of a key pathway associated with endoplasmic reticulum stress.

3 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Computational tools reveal how blood enzyme works at the atomic level

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Researchers investigate the neutralizing antibody activity against different variants of SARS-CoV-2 in fully immunized elderly individuals.

3 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

Once-a-day antiretroviral medicine for children proven to be more effective at suppressing HIV

A once-a-day antiretroviral medicine that is low-cost and easy for children to take is also more effective at suppressing HIV than standard treatments, according to a global trial led by researchers at UCL.

30 Dec 2021

Enzyme News and Research

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Erectile dysfunction medication found to intensify abdominal aortic aneurysms in mice

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Transplant recipients benefit from a COVID-19 vaccine booster

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

SARS-CoV-2 differs from other betacoronaviruses in a key IRE1α/XBP1 pathway

The impact of natural selection on sequence diversity in SARS-CoV-2

Computational tools reveal how blood enzyme works at the atomic level

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

Once-a-day antiretroviral medicine for children proven to be more effective at suppressing HIV

Biochemical Assays for Efficient Hit Prioritization After Screening eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo